登入
選單
返回
Google圖書搜尋
Cancer Immunotherapy
Hongtao Zhang
Arabinda Samanta
Yasuhiro Nagai
Hiromichi Tsuchiya
Takuya Ohtani
Zheng Cai
Zhiqiang Zhu
Jing Liu
Mark I. Greene
其他書名
Chapter 14. Monoclonal Antibodies for Cancer Therapy and Prevention: Paradigm Studies in Targeting the neu/ERBB2/HER2 Oncoprotein
出版
Elsevier Inc. Chapters
, 2013-06-04
主題
Medical / Immunology
Science / Life Sciences / Biology
Medical / Oncology
Science / Life Sciences / Cell Biology
ISBN
0128059109
9780128059104
URL
http://books.google.com.hk/books?id=YRB1DAAAQBAJ&hl=&source=gbs_api
EBook
SAMPLE
註釋
The foundation for targeted therapy of cancers driven by members of the ErbB oncoprotein family was established initially by the demonstration that ectodomain binding monoclonal antibodies (mAb) could disable the protein kinase encoded by the HER2/neu oncogene. Homomeric and heteromeric erbB kinases play critical roles in the development of cancer and in the spread of early lesions. In particular, antibodies targeting the p185erbB2/neu receptor provide major clinical benefits in the treatment of breast cancer and also stomach cancer. As suggested by our study with oncogenic neu transgenic mice, anti-p185erbB2/neu antibodies are also effective in preventing the tissue hyperplasia that precedes tumorigenesis, tumor growth and the dissemination of ErbB2/neu kinase-positive cells into other tissues. As a therapeutic principle, “reversion of phenotype” for established tumors and “prevention” of tumorigenesis and spread can explain the basis for the benefits invoked by therapeutic and adjuvant therapies for breast cancer patients after cancers are surgically removed. These emerging principles being enlightened by ongoing studies of monoclonal antibody therapy will continue to provide guidance for the development of new targeted therapies for resistant tumors that arise after treatment.